Cited by 311Cancer survivorship and careMobile Health and mHealth ApplicationsTelemedicine and Telehealth Implementation

Phase III Randomized Controlled Trial of eRAPID: eHealth Intervention During Chemotherapy

Open access
Absolom, Kate, Warrington, Lorraine, Hudson, Eleanor, Hewison, Jenny, Morris, Carolyn, Holch, Patricia, Carter, Robert, Gibson, Andrea +12 more·2021·Journal of Clinical Oncology

Abstract

PURPOSE: Electronic patient self-Reporting of Adverse-events: Patient Information and aDvice (eRAPID) is an online eHealth system for patients to self-report symptoms during cancer treatment. It provides automated severity-dependent patient advice guiding self-management or medical contact and displays the reports in electronic patient records. This trial evaluated the impact of eRAPID on symptom control, healthcare use, patient self-efficacy, and quality of life (QOL) in a patient population treated predominantly with curative intent. METHODS: Patients with colorectal, breast, or gynecological cancers commencing chemotherapy were randomly assigned to usual care (UC) or the addition of eRAPID (weekly online symptom reporting for 18 weeks). Primary outcome was symptom control (Functional Assessment of Cancer Therapy-General, Physical Well-Being subscale [FACT-PWB]) assessed at 6, 12, and 18 weeks. Secondary outcomes were processes of care (admissions or chemotherapy delivery), patient self-efficacy, and global quality of life (Functional Assessment of Cancer Therapy–General, EQ5D-VAS, and EORTC QLQ-C30 summary score). Multivariable mixed-effects repeated-measures models were used for analyses. Trial registration: ISRCTN88520246. RESULTS: Participants were 508 consenting patients (73.6% of 690 eligible) and 55 health professionals. eRAPID compared to UC showed improved physical well-being at 6 ( P = .028) and 12 ( P = .039) weeks and no difference at 18 weeks (primary end point) ( P = .69). Fewer eRAPID patients (47%) had clinically meaningful physical well-being deterioration than UC (56%) at 12 weeks. Subgroup analysis found benefit in the nonmetastatic group at 6 weeks ( P = .0426), but not in metastatic disease. There were no differences for admissions or chemotherapy delivery. At 18 weeks, patients using eRAPID reported better self-efficacy ( P = .007) and better health on EQ5D-VAS ( P = .009). Average patient compliance with weekly symptom reporting was 64.7%. Patient adherence was associated with clinician's data use and improved FACT-PWB at 12 weeks. CONCLUSION: Real-time monitoring with electronic patient-reported outcomes improved physical well-being (6 and 12 weeks) and self-efficacy (18 weeks) in a patient population predominantly treated with curative intent, without increasing hospital workload.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.20.02015

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 3

  1. Mort D, Lansdown M, Smith N, et al: For Better, for Worse? A Review of the Care of Patients Who Died Within 30 Days of Receiving Systemic Anti-cancer Therapy National Confidential Enquiry Into Patient Outcome and Death (NCEPOD), London, 2008
  2. Howell D, Mayer DK, Fielding R, et al: Management of cancer and health after the clinic visit: A call to action for self-management in cancer care. J Natl Cancer Inst 10.1093/jnci/djaa083 [epub ahead of print on June 11, 2020] · DOI
  3. American Medical Association: AMA quick guide to telemedicine in practice. https://www.ama-assn.org/practice-management/digital/ama-quick-guide- telemedicine-practice. Accessed June 5, 2020

Cited by

Sorted by citations

Authors
Absolom, K., Warrington, L., Hudson, E., Hewison, J., Morris, C., Holch, P., Carter, R., Gibson, A., Holmes, M., Clayton, B., Rogers, Z., McParland, L., Conner, M., Glidewell, L., Woroncow, B., Dawkins, B., Dickinson, S., Hulme, C., Brown, J., & Velikova, G.
Affiliations
  • University of Leeds (GB)
  • Patient Representative, Independent Cancer Patients Voices, Brighton, United Kingdom
Venue
Journal of Clinical Oncology
Published
2021-03-01
Volume
39
Issue
7
Pages
734-747
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W3118788544
Cited by
311
References
37
Citations by year
2026: 49 · 2025: 60 · 2024: 59 · 2023: 50 · 2022: 59 · 2021: 34
FWCI
18.38
Type
journal article
Language
en
Open access
Locations
  • Journal of Clinical Oncology (publishedVersion)
  • PubMed (publishedVersion)
  • White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (acceptedVersion)
  • Open Research Exeter (University of Exeter) (acceptedVersion)
  • Figshare (submittedVersion)
Funders
  • Pfizer
  • National Institute for Health and Care Research (RP-PG-0611-20008, RP-DG-1209-10031)
Topics
  • Health Sciences › Medicine › Oncology › Cancer survivorship and care
  • Health Sciences › Health Professions › General Health Professions › Mobile Health and mHealth Applications
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Telemedicine and Telehealth Implementation
Keywords
digital health interventions, chemotherapy side effects, symptom management, physical well-being, patient self-efficacy, quality of life, health care utilization, real-time symptom monitoring, colorectal cancer, breast cancer, gynecologic cancer, patient adherence, electronic health records, EQ-5D
MeSH terms
Patient Reported Outcome Measures, Adolescent, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, England, Female, Hospitalization, Humans, Male, Middle Aged, Neoplasms, Prospective Studies, Quality of Life, Therapy, Computer-Assisted, Time Factors, Treatment Outcome, Telemedicine, Self Efficacy, Young Adult, Electronic Health Records, Symptom Assessment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review